While several groups have demonstrated the feasibility of accessing and analyzing circulating tumor (3, 6, 40, 41), current approaches are largely limited by their reliance on EpCAM as a cell surface marker with which to differentiate tumor from WBCs in the blood or marrow. This evidence concerns the gene EPCAM and neoplasm.